Pharsight

Elepsia Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425938 TRIPOINT Pharmaceutical composition
Feb, 2026

(1 year, 9 months from now)

US8535717 TRIPOINT Pharmaceutical composition
Feb, 2026

(1 year, 9 months from now)

US8163306 TRIPOINT Oral drug delivery system
Sep, 2027

(3 years from now)

US8470367 TRIPOINT Oral drug delivery system
Oct, 2027

(3 years from now)

US8431156 TRIPOINT Pharmaceutical composition
Oct, 2027

(3 years from now)

Elepsia Xr is owned by Tripoint.

Elepsia Xr contains Levetiracetam.

Elepsia Xr has a total of 5 drug patents out of which 0 drug patents have expired.

Elepsia Xr was authorised for market use on 20 December, 2018.

Elepsia Xr is available in tablet, extended release;oral dosage forms.

The generics of Elepsia Xr are possible to be released after 31 October, 2027.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 20 December, 2018

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

ELEPSIA XR family patents

Family Patents